Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Lia Scribano

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Digestive Diseases and Sciences|October 19, 2020
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?Maria Lia Scribano
Mini Reviews in Medicinal Chemistry|July 24, 2015
Role of Rifaximin in Inflammatory Bowel Disease TreatmentMaria Lia Scribano
World Journal of Gastroenterology|June 23, 2018
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidenceMaria Lia Scribano
Current Opinion in Gastroenterology|May 16, 2009
Antibiotics and probiotics in inflammatory bowel disease: why, when, and howCosimo Prantera, Maria Lia Scribano
World Journal of Gastroenterology|February 23, 2013
Use of antibiotics in the treatment of Crohn's diseaseMaria Lia Scribano, Cosimo Prantera
Digestive Diseases (Basel, Switzerland)|November 20, 2013
Antibiotics and inflammatory bowel diseasesMaria Lia Scribano, Cosimo Prantera
Expert Opinion on Pharmacotherapy|February 4, 2014
Budesonide multi-matrix system formulation for treating ulcerative colitisCosimo Prantera, Maria Lia Scribano
World Journal of Gastroenterology|November 22, 2013
Rifaximin and Crohn's diseaseCosimo Prantera, Maria Lia Scribano
Reviews on Recent Clinical Trials|October 25, 2012
Randomized controlled trials in steroid dependent and in severe colitisMaria Lia Scribano, Laura Cantoro, Luigi Giovanni Papparella, et al.
Journal of Clinical Gastroenterology|March 27, 2014
Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature reviewMaria Lia Scribano, Laura Cantoro, Marzia Marrollo, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Digestive Diseases and Sciences|October 19, 2020
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?Maria Lia Scribano
Mini Reviews in Medicinal Chemistry|July 24, 2015
Role of Rifaximin in Inflammatory Bowel Disease TreatmentMaria Lia Scribano
World Journal of Gastroenterology|June 23, 2018
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidenceMaria Lia Scribano
Current Opinion in Gastroenterology|May 16, 2009
Antibiotics and probiotics in inflammatory bowel disease: why, when, and howCosimo Prantera, Maria Lia Scribano
World Journal of Gastroenterology|February 23, 2013
Use of antibiotics in the treatment of Crohn's diseaseMaria Lia Scribano, Cosimo Prantera
Digestive Diseases (Basel, Switzerland)|November 20, 2013
Antibiotics and inflammatory bowel diseasesMaria Lia Scribano, Cosimo Prantera
Expert Opinion on Pharmacotherapy|February 4, 2014
Budesonide multi-matrix system formulation for treating ulcerative colitisCosimo Prantera, Maria Lia Scribano
World Journal of Gastroenterology|November 22, 2013
Rifaximin and Crohn's diseaseCosimo Prantera, Maria Lia Scribano
Reviews on Recent Clinical Trials|October 25, 2012
Randomized controlled trials in steroid dependent and in severe colitisMaria Lia Scribano, Laura Cantoro, Luigi Giovanni Papparella, et al.
Journal of Clinical Gastroenterology|March 27, 2014
Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature reviewMaria Lia Scribano, Laura Cantoro, Marzia Marrollo, et al.
Pageof 4